J. Safra Sarasin Holding Ag Viridian Therapeutics, Inc.\De Transaction History
J. Safra Sarasin Holding Ag
- $5.79 Trillion
- Q2 2025
A detailed history of J. Safra Sarasin Holding Ag transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, J. Safra Sarasin Holding Ag holds 171,119 shares of VRDN stock, worth $2.99 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
171,119
Previous 72,672
135.47%
Holding current value
$2.99 Million
Previous $980 Million
144.2%
% of portfolio
0.04%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding VRDN
# of Institutions
188Shares Held
79.7MCall Options Held
92.2KPut Options Held
55.2K-
Deep Track Capital, LP Greenwich, CT5.38MShares$94.1 Million2.54% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$83.5 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.7MShares$82.2 Million5.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.56MShares$79.8 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$67.9 Million12.64% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $698M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...